Medical device Testing Lab as a Service (TLaaS)

Medical device manufacturers today face unprecedented challenges. Modern devices integrate software, cloud connectivity, wireless protocols, and AI/ML capabilities alongside traditional hardware and biocompatible materials, creating increased complexity. Regulatory pathways and market dynamics demand faster validation cycles, compressing timelines considerably.

Specialized testing expertise — particularly in automation frameworks, continuous integration/continuous deployment (CI/CD), and software validation — remains in critically short supply across the industry. Meanwhile, health care purchasers demand lower costs while hospitals face eroding margins, creating downward pressure on device pricing and limiting capital expenditure for testing infrastructure. In this context, outsourced testing infrastructure has evolved from a tactical cost-reduction mechanism into a strategic platform for competitive advantage.

From product-centric to service-centric quality

Research from leading Medtech organizations reveals a fundamental shift. Rather than competing solely on product differentiation — where incremental hardware innovations yield diminishing returns — forward-thinking manufacturers compete on delivering integrated solutions combining hardware, software, data analytics, and services. As implantable devices become increasingly commoditized, manufacturers are shifting from a “product-dominant logic” to a “service-dominant logic.”

In traditional product-dominant models, testing serves a gatekeeping function, quality is defined as compliance with specifications, and the organization optimizes cost reduction and speed. In emerging service-dominant models, testing becomes an ongoing feedback mechanism supporting continuous improvement, customer outcomes define quality, and the organization optimizes reliability, rapid iteration, and data-driven decision-making.

TLaaS aligns naturally with service-dominant logic because it enables manufacturers to access specialized expertise without permanent infrastructure, scale testing capacity elastically, leverage continuous integration frameworks for rapid iteration, and maintain focus on clinical outcomes rather than operational complexity.

Technical architecture — The modern testing lab as platform

The automated test case (ATC) laboratory at GE HealthCare provides concrete insights into the evolution of modern testing infrastructure. This case study — documenting the transition from outsourced to optimized in-house infrastructure — reveals critical principles for TLaaS platform design.

Hardware Integration: Modern testing laboratories require modular hardware configurations adaptable for different test scenarios, iterative setup approaches allowing validation before full-scale deployment, and integration with production environments such as hospital networks. TLaaS providers must offer configurable hardware portfolios — from simplified setups for basic compatibility testing to fully instrumented environments replicating clinical conditions.

Software and Dependency Management: Critical challenges include undocumented dependencies emerging only through iterative testing and version management complexity across multiple software layers. Modern TLaaS platforms address this through containerized environments (Docker, Kubernetes), version-controlled test specifications, and automated dependency resolution.

Continuous Integration: Advanced TLaaS providers offer fully integrated CI/CD pipelines that trigger testing automatically when device software is updated, maintain comprehensive test result databases for trend analysis, enable regression testing at scale and generate real-time compliance documentation.

Iterative Development: The transition from outsourced to in-house testing at GE HealthCare succeeded through iterative validation and optimization, not direct replication. Service providers must support iterative refinement of test specifications, proof-of-concept phases, progressive complexity, and continuous feedback loops between development and testing teams.

Business model evolution — Testing as a strategic service

Traditional outsourced testing operates on a transaction model where manufacturers submit specifications, labs execute tests and results are returned. Advanced TLaaS operates on a partnership model featuring joint test strategy aligned with regulatory pathways, ongoing collaboration on optimization and shared accountability for quality metrics. Organizations that implemented equipment management outsourcing in hospitals report that the highest-performing vendors were those who transitioned to collaborative partnerships focused on shared outcomes.

Service providers create differentiated value through deep domain expertise, investment in advanced equipment and automation, continuous improvement methodologies and predictive analytics. Premium TLaaS providers offer expertise in test optimization, automation frameworks, regulatory strategy, and risk mitigation — not just lab access.

Advanced TLaaS providers offer full lifecycle services: front-end services including requirements analysis and test strategy; core services such as test execution and compliance documentation; continuous improvement services encompassing trend analysis and root cause investigation; and back-end services covering regulatory submission support and post-market surveillance integration.

Market drivers and business case

Talent and Expertise Scarcity: The shortage of specialized professionals is acute. Software quality assurance expertise requires training in both medical device regulatory requirements and modern software development — a rare combination. Automation framework expertise, particularly in tools like Robot Framework, is scarce. Organizations face the choice of recruiting expensive specialized talent or partnering with providers who maintain this expertise at scale.

Infrastructure Investment Barriers: Modern testing environments require significant capital investment in laboratory facilities with environmental controls, equipment libraries, software infrastructure and network infrastructure. TLaaS providers amortize these costs across multiple clients, reducing per-device testing costs.

Speed to Market: Software-enabled devices iterate rapidly, regulatory pathways increasingly demand real-time compliance monitoring and clinical feedback loops require the ability to validate changes quickly. Traditional internal labs struggle with fixed capacity, long procurement timelines and batch testing cycles. TLaaS providers maintain flexible capacity and can rapidly adapt.

Focus on Core Competency: Successful service adoption occurs when companies focus resources on competitive differentiators. For device manufacturers, core competencies include clinical innovation, user experience design and customer relationships. By outsourcing testing, manufacturers redirect engineering resources toward innovation.

Practical implementation – TLaaS in action

Selective Outsourcing: Many organizations adopt a hybrid approach, retaining critical path testing and regulatory submission decisions internally while outsourcing high-volume routine testing, specialized domains and automation framework maintenance. For example, a cardiovascular device manufacturer might retain hemodynamic performance testing internally but outsource software compatibility and electromagnetic compliance testing.

Full-Lifecycle Partnership: More mature implementations involve service providers as extended teams with embedded resources, joint test planning, real-time result visibility and shared accountability for regulatory submissions.

Platform-Based Model: Emerging TLaaS providers offer cloud-based platforms enabling manufacturer specification of test requirements, automated test execution monitoring, real-time compliance documentation generation and integration with product development systems.

Regulatory and quality considerations

A critical concern is whether outsourced testing can maintain the quality, traceability and regulatory compliance required by FDA, CE marking and other frameworks. Research on medical equipment management outsourcing provides reassuring evidence: organizations that implemented comprehensive outsourcing while maintaining oversight structures improved performance on equipment utilization, clinical satisfaction, cost control and regulatory compliance.

The successful oversight model includes clear performance metrics established upfront, regular audits of provider processes, quality gate reviews, escalation protocols and real-time data transparency. TLaaS maintains regulatory integrity through the provider’s FDA registration and quality certification, complete audit trails with electronic records, protocol control within the manufacturer’s quality system, independent verification of critical results and formal change management with documented traceability.

Case study — GE HealthCare

GE HealthCare’s experience transitioning the ATC laboratory from outsourced to optimized in-house setup reveals critical lessons. The original outsourced system had undocumented dependencies apparent only during iterative testing, underscoring the importance of evaluating providers on documentation quality. Rather than direct replication, GE HealthCare built capability through iterative proof-of-concept approaches with progressively increasing complexity — suggesting pilot programs should start with simplified, lower-risk scenarios.

Successful transition required adapting the outsourced system to integrate with existing infrastructure rather than recreating an identical external system. The system used Robot Framework and Selenium for automation, managed through Git repositories and Docker containers — modern approaches more maintainable than legacy commercial tools. These findings suggest preferring providers using open-source tools with active development communities.

Servitization and the future of testing services

Leading service providers position themselves not as “test labs” but as integral partners in product success. The shift moves from vendor to advisor — offering analysis, trend insights and optimization recommendations rather than simple pass/fail results. Testing evolves from a compliance requirement to a competitive advantage, generating insights that drive innovation. Value-added services include cross-client trend analysis, benchmarking against industry standards, regulatory strategy consultation and risk prediction models identifying field issues before launch. The model shifts from batch to continuous, integrating testing with agile development cycles for real-time feedback.

Challenges and risk mitigation

Concerns about loss of control are mitigated through formal SLAs with specific performance metrics, regular quality audits and site visits, real-time access to compliance documentation and escalation protocols for unexpected results. Studies show organizations with strong governance structures achieve better compliance metrics than those operating purely internally. Intellectual property concerns are addressed through specific IP protection clauses, confidentiality agreements, tiered access models where only essential information is shared and robust security protocols. Capacity and responsiveness risks are managed through reservation agreements with guaranteed response times, multiple provider relationships for redundancy and pilot phases to establish reliability. The changing regulatory landscape is addressed by partnering with providers who actively participate in standards development and establishing contractual mechanisms for updating test protocols.

Implementation roadmap

During assessment and preparation (months 1-3), organizations document current testing operations, identify outsourcing candidates, evaluate the provider landscape and define success metrics. The pilot program design phase (months 3–6) involves selecting a lower-risk domain, establishing governance structures, issuing RFQ/RFP and planning integration. During Pilot Execution (months 6–12), organizations launch the pilot, monitor performance, capture learnings and evaluate expansion criteria. Expansion and optimization (months 12+) extends outsourcing to additional domains, matures processes and leverages testing insights for competitive advantage.

Differentiated models

The traditional product-dominant model positions QA as gatekeeper, focusing on static validation protocols (IQ/OQ/PQ), GDP document integrity and SOP adherence under ISO 13485 and FDA 21 CFR Part 11. Its limitations include limited adaptability for rapid SDLC changes, heavy CAPEX and slower feedback loops.

The emerging service-dominant model focuses on continuous feedback using risk-based verification and validation. Labs adopt pay-as-you-go infrastructure, scalable QA capacity, continuous integration, AI-driven testing and predictive analytics, transitioning from static to continuous CSV validation per FDA CSA guidance and GAMP5 principles.

The most recommended service factory model (TLaaS) offers independent verification and validation across the full lifecycle — conceptualization through sustainment. It provides lab infrastructure and automation frameworks (LabVIEW, Selenium, AI-based tools), automated generation of validation protocols and QMS integration for submission-ready documentation, shifting from “requirements verification” to “experience verification” encompassing usability, reliability and clinical fit.

Concrete industry examples

Software Validation for Connected Devices: A Medtech organization developing connected glucose monitoring systems partnered with a specialized testing provider for software compatibility testing across smartphone platforms, wireless connectivity validation, cybersecurity testing and continuous integration. The result was a 40% reduction in time to release software updates, improved reliability and reduced internal QA staffing needs.

Biocompatibility and Materials Testing: A cardiovascular device manufacturer outsourced biocompatibility validation to specialized ISO 10993 laboratories while retaining material selection, test strategy, results interpretation and regulatory coordination internally. The result was access to specialized expertise, faster clinical evaluation submission and reduced facility overhead.

Full-Lifecycle Equipment Management: Hospitals implementing comprehensive medical equipment management outsourcing demonstrated utilization rates up 15–20%, satisfaction up 25%+, cost reductions of 20–30%, enhanced predictive maintenance through data analytics and improved compliance through structured oversight.

Conclusion: The TLaaS imperative

Medical Device Testing Lab as a Service represents more than a tactical outsourcing decision. It reflects a fundamental strategic shift in how Medtech organizations compete and innovate. Servitization is reshaping the industry, and TLaaS fits naturally within this evolution. Modern testing is too complex for most organizations to maintain internally; the combination of software, hardware, connectivity and AI/ML exceeds most manufacturers’ expertise. TLaaS enables speed and agility where software updates iterate in weeks and regulatory guidance evolves continuously. Full-lifecycle partnerships create the most value, and governance mechanisms ensure quality and compliance. The future belongs to integrated platforms combining automated test execution, compliance documentation and continuous improvement analytics.

For manufacturers considering TLaaS, start with a pilot in a lower-risk domain with defined success criteria; seek providers who serve as strategic advisors; invest in governance with strong oversight systems; plan for integration with providers whose platforms connect cleanly with development systems; and build for flexibility with service models that evolve with changing needs.

The organizations that will lead in the next era of Medtech innovation are those that master outsourced testing partnerships, freeing internal resources to focus on what truly differentiates them: clinical innovation, user experience design, and customer outcomes.

Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.

Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He is currently SVP, Life Sciences, at Coforge Limited, a $1.7B multinational digital solutions and technology consulting services company. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC.

Partha Khot is the Life Sciences Practice Lead at Coforge, a $1.7B multinational digital solutions and technology consulting services company focused on driving innovation at the intersection of domain and technology. He held leadership roles at Triomics, Abbott, and Citiustech, driving health care innovation & consulting across the US, Europe, and India. Partha is responsible for developing next-generation Life Sciences Solutions at Coforge, built on Industry Platforms and differentiated through AI/Automation accelerators.

Prashant Deshpande is an internationally experienced IT executive with extensive business leadership, service design & delivery, and operations skills across the NA, LATAM, and Europe regions. He is currently VP, Life Sciences, at Coforge Limited. He brings 25+ years of solid IT services experience in the digital space and has held senior leadership roles at large-scale IT companies such as Cognizant, Capgemini, L&T Mindtree, and CMC, where he built service lines and competency units, managed P&L, and led large-scale, complex delivery and transformation programs across multiple domains, including HCLS.